Beta Globulins, E.g., Transferrin, Etc. Patents (Class 530/394)
-
Publication number: 20110256104Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: ApplicationFiled: May 13, 2011Publication date: October 20, 2011Applicants: CALANDO PHARMACEUTICALS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng
-
Publication number: 20110256156Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.Type: ApplicationFiled: May 20, 2011Publication date: October 20, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Jon E. Chatterton, Abbot F. Clark
-
Publication number: 20110245178Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: ApplicationFiled: November 30, 2010Publication date: October 6, 2011Applicant: BIOREXIS PHARMACEUTICAL CORPORATIONInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20110218327Abstract: The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a ?-lactoglobulin product and the isolation of an ?-enriched whey protein isolate from whey obtained from an animal. The ?-enriched whey protein isolate provided by the present invention is besides from being low in ?-lactoglobulin also high in ?-lactalbumin and immunoglobulin G.Type: ApplicationFiled: September 29, 2009Publication date: September 8, 2011Applicant: Upfront Chromatography A/SInventors: Marie Bendix Hansen, Allan Otto Fog Lihme, Malene Fog Lihme
-
Publication number: 20110183860Abstract: Using the Sup35 prion proteins of two distantly related yeast species, it is established that prion replication is initiated by small elements of primary sequence, which can be identified using arrays of short peptides. Subtle differences in replication elements govern the formation of distinct aggregate conformations (prion strains) and also determine their species-specific seeding activities. A Sup35 chimera that promiscuously forms prions in more than one species does so by virtue of carrying the replication element of each species. Mutations or conditions that cause the chimera to assemble into distinct prion strains favor recognition of distinct replication elements. Therefore, subtle differences in small sequences that constitute prion replication elements encode important determinants of prion propagation and transmission.Type: ApplicationFiled: September 13, 2007Publication date: July 28, 2011Applicant: Whitehead Institute for Biomedical ResearchInventors: Susan Lindquist, Peter Tessier
-
Publication number: 20110158906Abstract: The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5? end of said second nucleic acid molecule; and/or (b) a hydrophobic polymer attached to the 3? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3? end of said second nucleic acid molecule.Type: ApplicationFiled: August 13, 2008Publication date: June 30, 2011Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Klaus Müllen, Fikri E. Alemdaroglu, Andreas Herrmann, N. Ceren Alemdaroglu, Peter Langguth
-
Publication number: 20110142756Abstract: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.Type: ApplicationFiled: October 4, 2010Publication date: June 16, 2011Inventors: George L. Mayers, Samuel Rose, David S. Rose
-
Publication number: 20110124576Abstract: Based on the three-dimensional structure of transferrin, the inventors have designed variant polypeptides (muteins) which have one or more Cysteine residues with a free thiol group (hereinafter referred to as thiotransferrin). The variant polypeptide may be conjugated through the sulphur atom of the Cysteine residue to a bioactive compound.Type: ApplicationFiled: August 8, 2008Publication date: May 26, 2011Applicant: Novozymes A/SInventors: Darrell Sleep, Joanne Hay, Esben Peter Friis
-
Publication number: 20110092442Abstract: An anticancer agent containing BL-angiostatin as an active ingredient; and a process for producing the same. Also a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of BL-angiostatin.Type: ApplicationFiled: February 24, 2004Publication date: April 21, 2011Applicant: TTC CO., LTDInventors: Keiji Hasumi, Kosuke Shimizu, Tetsuro Yamamoto
-
Publication number: 20110086768Abstract: Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.Type: ApplicationFiled: December 7, 2007Publication date: April 14, 2011Applicant: BIOREXIS PHARMACEUTICAL CORPORATIONInventors: Andrew John Turner, Baiyang Wang
-
Publication number: 20110064733Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: ApplicationFiled: October 26, 2010Publication date: March 17, 2011Applicant: IMMUNOGEN, INC.Inventors: Gillian PAYNE, Philip Chun, Daniel J. Tavares
-
Publication number: 20110065197Abstract: [Problems] The differential diagnosis of Alzheimer's disease as distinguished from other type of dementia and the diagnosis of Alzheimer's disease at such an early stage where neural cell death has not proceeded yet are important for the treatment of Alzheimer's disease. On the other hand, it is difficult to differentially diagnose Alzheimer's disease at an earlier stage by a diagnosis mainly made by questioning by a doctor or a diagnostic technique using phosphorylated tau or amyloid-? protein as an indicator. Thus, the development of a novel diagnostic technique has been demanded. [Means for Solving Problems] An attention is focused on transferrin having a sugar chain attached thereto. Thus, disclosed are a diagnostic kit, a diagnostic marker and a detection method for differentially diagnosing the disease condition of Alzheimer's disease at an earlier stage.Type: ApplicationFiled: September 6, 2007Publication date: March 17, 2011Applicant: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITYInventors: Katsuya Urakami, Miyako Kimura
-
Publication number: 20110059889Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: December 18, 2009Publication date: March 10, 2011Inventors: ADAM R. MEZO, KEVIN A. MCDONNELL, CRISTINA A. TAN HEHIR, ALFREDO CASTRO
-
Publication number: 20110053842Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: February 10, 2009Publication date: March 3, 2011Applicant: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
-
Publication number: 20110046062Abstract: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.Type: ApplicationFiled: November 1, 2010Publication date: February 24, 2011Inventors: Peter Gronski, Christoph Licht, Bernd Hoppe, Peter Zipfel, Christine Skerka
-
Publication number: 20110044931Abstract: The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency.Type: ApplicationFiled: April 29, 2009Publication date: February 24, 2011Applicant: KOREA ADVANCE INSTITUTE OF SCIENCE AND TECHNOLOGYInventor: Tae Gwan Park
-
Publication number: 20110038809Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.Type: ApplicationFiled: October 31, 2006Publication date: February 17, 2011Inventors: Daniel P. Perl, Sharon Moalem
-
Publication number: 20110021744Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.Type: ApplicationFiled: October 8, 2010Publication date: January 27, 2011Applicant: ImmunoGen, Inc.Inventors: Yong DAI, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
-
Publication number: 20110003362Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: July 12, 2010Publication date: January 6, 2011Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
-
Publication number: 20110003969Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: June 3, 2010Publication date: January 6, 2011Applicant: Immunogen Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20100310673Abstract: An agent for thermally stabilizing lactoferrin, which comprises a nucleic acid as an active ingredient, can be added to lactoferrin to impart thermal stability to lactoferrin. Thermally stabilized lactoferrin can be heat-sterilized at a pH value around a neutral pH value while keeping its activity.Type: ApplicationFiled: March 31, 2009Publication date: December 9, 2010Applicant: MORINAGA MILK INDUSTRY CO., LTD.Inventors: Ayako Horigome, Mai Murata, Koji Yamauchi, Mitsunori Takase, Yasuhiro Takeda, Junichi Hashimoto, Ikumi Kojima
-
Publication number: 20100310597Abstract: A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. Immunoassay that measures the compound shown by the formula (I) that has not been metabolized is implemented using the above antibody.Type: ApplicationFiled: December 15, 2008Publication date: December 9, 2010Inventor: Osamu Miyazaki
-
Publication number: 20100297762Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.Type: ApplicationFiled: August 5, 2010Publication date: November 25, 2010Applicant: Ariel-University Research and Developmemt Company Ltd.Inventors: Michael A. FIRER, Raisa Laptev
-
Publication number: 20100279927Abstract: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.Type: ApplicationFiled: July 16, 2010Publication date: November 4, 2010Inventors: Zee Upton, Jennifer Ann Kricker
-
Publication number: 20100273718Abstract: Hydrolyzate compositions comprising at least one milk protein or whey hydrolyzed with at least one proteolytic enzyme are provided. The hydrolyzates reduce the immunogenicity of the milk or whey protein in a subject predisposed to having an immune reaction to the protein. Methods for making the compositions are also provided, as food products and nonfood products comprising the compositions.Type: ApplicationFiled: December 3, 2007Publication date: October 28, 2010Applicant: Danisco A/SInventors: Manoj Kumar, David Wong
-
Publication number: 20100256332Abstract: The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homologue of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2-homologue/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.Type: ApplicationFiled: March 27, 2008Publication date: October 7, 2010Inventors: Christine Wallrapp, Eric Thoenes, Peter Geigle
-
Publication number: 20100222267Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.Type: ApplicationFiled: June 13, 2008Publication date: September 2, 2010Applicant: Novozymes Biopharma UK Limited.Inventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
-
Publication number: 20100210821Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).Type: ApplicationFiled: August 25, 2008Publication date: August 19, 2010Inventors: Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
-
Publication number: 20100210513Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.Type: ApplicationFiled: April 30, 2010Publication date: August 19, 2010Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
-
Patent number: 7772179Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.Type: GrantFiled: April 20, 2006Date of Patent: August 10, 2010Assignee: Ariel-University Research and Development Company Ltd.Inventors: Michael A. Firer, Raisa Laptev
-
Publication number: 20100144622Abstract: Methods of producing properly refolded recombinant plasminogen and plasmin polypeptide are provided. Denatured recombinant plasminogen polypeptide is refolded by first solubilizing the polypeptide with a chaotroph and reducing and oxidizing agents at high pH, followed by refolding in the presence of reduced concentration of chaotroph and reducing and oxidizing agents and in the presence of arginine.Type: ApplicationFiled: September 28, 2007Publication date: June 10, 2010Inventors: Xinli Lin, Daniel Medynski
-
Publication number: 20100145021Abstract: A process for enhancing the recovery yield of proteins, especially plasma proteins, from sources containing the proteins, wherein the sources containing the proteins are frozen at temperatures of ??70° C., and the proteins from a frozen source after thawing are further processed in a per se known manner.Type: ApplicationFiled: January 25, 2008Publication date: June 10, 2010Inventor: Wolfgang Marguerre
-
Publication number: 20100137557Abstract: Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death.Type: ApplicationFiled: October 22, 2009Publication date: June 3, 2010Applicant: CanCure Laboratories LLCInventor: Zoltan KISS
-
Publication number: 20100121033Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: November 21, 2007Publication date: May 13, 2010Applicant: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
-
Publication number: 20100074847Abstract: Chromophore probes that are capable of being taken up by, retained by or bound to a biocompatible molecule to form an imaging construct are provided. Various activation strategies of the resulting imaging construct are also provided.Type: ApplicationFiled: March 23, 2009Publication date: March 25, 2010Inventors: Karen N. Madden, Kirtland G. Poss
-
Patent number: 7658917Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: June 17, 2003Date of Patent: February 9, 2010Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Ethan R. Signer, James Wakefield, Laura Kasman, Gary Musso, Michael J. Reed
-
Publication number: 20090304713Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: ApplicationFiled: November 24, 2008Publication date: December 10, 2009Applicants: AMGEN INC., UCB PHARMA S.A.Inventors: Christoper Paszty, Martin Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron George Winters
-
Publication number: 20090275481Abstract: Fusion proteins comprising a transferrin moiety, a stalk moiety, and cell wall linking member and peptide libraries thereof are disclosed. The present invention includes a method of screening peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.Type: ApplicationFiled: June 19, 2006Publication date: November 5, 2009Applicant: Pfizer, Inc.Inventors: Baiyang Wang, Andrew Turner
-
Publication number: 20090269843Abstract: Fusion proteins comprising a first protein fused to hemopexin are provided, said fusion proteins exhibit an increased circulation time.Type: ApplicationFiled: August 16, 2005Publication date: October 29, 2009Applicant: Novo Nordisk A/SInventors: Niels Blume, Jing Su, Ju Han, Lars Fogh Iversen
-
Publication number: 20090258424Abstract: The invention provides a method for delivering a nucleic acid to a cell using a targeting molecule that is bound non-covalently to the nucleic acid. Compositions and kits are also provided.Type: ApplicationFiled: March 1, 2007Publication date: October 15, 2009Applicant: Yale UniversityInventor: Yingqun Huang
-
Publication number: 20090258079Abstract: A biocompatible block copolymer having a hydrophobic segment composed of amino acid and hydroxycarboxylic acid and a hydrophilic segment composed of polyalkylene oxide, wherein the terminal not bonded to the hydrophilic segment of the hydrophobic segment is composed of an amino acid unit.Type: ApplicationFiled: October 2, 2006Publication date: October 15, 2009Inventors: Ryoichi Katakai, Kazuhiro Kohama, Yoshiki Suzuki
-
Publication number: 20090239795Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: ApplicationFiled: July 24, 2007Publication date: September 24, 2009Inventors: DAVID JAMES BALLANCE, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20090181048Abstract: The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making, as well as screening for, Tf conjugates with increased cellular association or cellular internalization. The present invention also provides Tf conjugates with increased cellular association and internalization for delivering nucleic acids to cancer cells.Type: ApplicationFiled: June 6, 2008Publication date: July 16, 2009Applicant: The Regents of the University of CaliforniaInventors: Daniel T. Kamei, Bert J. Lao, Wen-Lin P. Tsai, Foad Mashayekhi, Edward A. Pham, Anne B. Mason
-
Publication number: 20090170163Abstract: The present invention relates to fusion proteins. The invention specifically relates to compositions and methods of Tf-based fusion proteins that demonstrate a high-level expression of transferrin (Tf)-based fusion proteins by inserting a helical linker between two protein domains.Type: ApplicationFiled: December 19, 2008Publication date: July 2, 2009Applicant: University of Southern CaliforniaInventors: Wei-Chiang Shen, Nurmamet Amet, Xiaoying Chen, Hsin-Fang Lee
-
Patent number: 7524932Abstract: A method for producing an oligomeric form of ?-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of ?-lactalbumin in which the ?-lactalbumin is preferably in the molten globule-like state, to an ion exchange medium which has been pre-treated with casein or an active component thereof, such as oleic acid, and recovering ?-lactalbumin in an oligomeric form therefrom. Pre-treatment of the ion exchange medium, particularly with casein derived from human milk, has been found to significantly improve yields of the oligomeric form of ?-lactalbumin and mean that it can readily isolated from readily available sources such as bovine ?-lactalbumin. This form of ?-lactalbumin is useful therapeutically, in particular as an antibacterial agent and also as an anti-cancer therapeutic.Type: GrantFiled: January 27, 2006Date of Patent: April 28, 2009Assignee: Nya Hamlet Pharma ABInventors: Catharina Svanborg, Per Anders Hakansson, Malin Wilhelmina Svensson
-
Publication number: 20090104210Abstract: Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described.Type: ApplicationFiled: October 7, 2008Publication date: April 23, 2009Inventors: Michael R. Tota, Shirly Pinto, Douglas J. MacNeil, Heather H. Zhou, Fubao Wang, Chen-Ni Chin
-
Publication number: 20090099336Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: ApplicationFiled: April 13, 2008Publication date: April 16, 2009Inventors: Gillian PAYNE, Philip Chun, Daniel J. Tavares
-
Publication number: 20090088370Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.Type: ApplicationFiled: March 29, 2006Publication date: April 2, 2009Applicant: Octapharma AGInventor: Stefan Winge
-
Publication number: 20090042777Abstract: A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone.Type: ApplicationFiled: October 8, 2004Publication date: February 12, 2009Inventors: Wei-Chiang Shen, Yun Bai, David Ann, Adam Widera
-
Publication number: 20080299612Abstract: A polypeptide comprising a first protein domain, a second protein domain, and a dithiocyclopeptide spacer containing at least one protease cleavage site, wherein the dithiocyclopeptide is exogenous relative to the first or second protein domain, and wherein the first and second protein domains are operably linked by the dithiocyclopeptide. Also disclosed are methods of producing the polypeptide and delivering the protein domains into a cell.Type: ApplicationFiled: March 28, 2008Publication date: December 4, 2008Applicant: University of Southern CaliforniaInventor: Wei-Chiang Shen